You just read:

Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal

News provided by

Nektar Therapeutics

May 22, 2020, 08:30 ET